natgillin/translations-raw huggingface dataset:
After your child has received Rotarix, contact your doctor/health care professional right away if your child experiences severe stomach pain, persistent vomiting, blood in stools, a swollen belly and/or high fever (see also section 4 “Possible side effects”).
Če se otroku, ki je dobil cepivo Rotarix, pojavijo hude bolečine v trebuhu, dolgotrajno bruhanje, kri v blatu, napihnjen trebuh in/ali močno zvišana telesna temperatura, se morate nemudoma posvetovati z zdravnikom ali drugim zdravstvenim osebjem (glejte tudi poglavje 4 »Možni neželeni učinki«).
After your condition has been brought under control, you will receive regular doses of Retacrit (3 times a week, or, if you have your injections under the skin, it may also be given once weekly or once every
Ko je stanje pod nadzorom, boste trikrat na teden dobivali običajni odmerek zdravila Retacrit ali, če si zdravilo injicirate pod kožo, lahko tudi enkrat na teden ali enkrat na dva tedna.
After your condition has been brought under control, you will receive regular doses of Silapo, 3 times a week.
Ko je Vaše stanje pod nadzorom, boste trikrat na teden dobivali običajni odmerek zdravila Silapo.
After your dose
Po odmerku
After your dosing is completed
Ko končate odmerjanje
After your injection with Eylea, you may experience some temporary visual disturbances.
Po injiciranju zdravila Eylea lahko pride do prehodnih motenj vida.
After your injection, fill in the used injection site and date in the table in your injection record (see the example: Keeping track of your injection sites and dates).
Po injekciji v tabelo v kartici vpišite datum in mesto injiciranja, ki ste ga uporabili (glejte primer: Zapisovanje mest injiciranja in datumov).
After your injection, fill in the used injection site and date in the table in your injection record (See the example: ‘Keeping track of your injection sites and dates’).
Po injiciranju v tabelo na kartici vpišite datum in mesto injiciranja, ki ste ga uporabili (glejte primer Zapisovanje mest injiciranja in datumov).
After your injection, fill in the used injection site and date on the table in your injection record (see the example: ‘Keeping track of your injection sites and dates’).
Po injiciranju v tabelo na kartici vpišite datum in mesto injiciranja, ki ste ga uporabili (glejte primer Zapisovanje mest injiciranja in datumov).
After your injection, leave the needle in the skin for five seconds to make sure you have taken the whole dose.
Po injiciranju pustite iglo v koži še pet sekund, da boste zagotovo prejeli celoten odmerek zdravila.
after you’ve left hospital: contact your doctor directly or go immediately to the Emergency Department of your nearest hospital -
ko zapustite bolnišnico: takoj obvestite svojega zdravnika oziroma takoj obiščite urgentni oddelek najbližje bolnišnice.
after you’ve left hospital: first seek advice from your doctor.
ko zapustite bolnišnico: najprej poiščite nasvet svojega zdravnika.
After you’ve waited for an hour, you can have your first food and drink of the day.
Ko ste počakali eno uro, lahko zaužijete prvo hrano ali pijačo.
After you’ve waited for an hour, you can have your first food and drink of the day.
Potem, ko ste počakali eno uro, lahko zaužijete svoj prvi dnevni obrok.
Afterward a single ‘booster’ can be given every six months to maintain the vaccine’s effect.
Vsakih šest mesecev je treba nato dati spodbujevalni odmerek za vzdrževanje učinka cepiva.
Afterward a single ‘booster’ should be given every year to maintain
Za vzdrževanje učinka cepiva je treba nato vsako leto psu injicirati osvežitveni
Afterwards it is performed monthly or as indicated by the doctor. checks of the serum protein known as lipase
Nato jo bodo opravljali mesečno ali po navodilih zdravnika. preveril serumsko beljakovino, znano kot lipaza
Afterwards, cats need a booster injection every year.
Mačke nato potrebujejo poživitveno injekcijo vsako leto.
AFTOVAXPUR DOE
(polipropilen)
AFTOVAXPUR DOE
A Turkey 14/98
AFTOVAXPUR DOE
A22 Iraq
AFTOVAXPUR DOE
AFTOVAXPUR
AFTOVAXPUR DOE
Asia1 Shamir
AFTOVAXPUR DOE
Steklenička
AFTOVAXPUR DOE emulsion for injection for cattle, sheep and pigs
AFTOVAXPUR DOE emulzija za injiciranje za govedo ovce in prašiče
AFTOVAXPUR DOE emulsion for injection for cattle, sheep and pigs
AFTOVAXPUR DOE emulzija za injiciranje za govedo, ovce in prašiče
Again open the roller clamp and let Respreeza flow until the filter is saturated.
Ponovno odprite stišček in pustite, da zdravilo Respreeza teče, dokler ni filter zasičen.
Again, all sites mentioned can be used regardless of your body type or size.
Uporabljajo se lahko vsa omenjena mesta, ne glede na vaš telesni tip ali velikost.
Again, do not touch the needle or allow it to touch any surface (see Diagram 11).
Pri tem zopet pazite, da se igle ne dotaknete ali z njo kam zadenete (glejte sliko 11).
Again, SLOWLY pull the white plunger rod out to 0.1 ml beyond the prescribed dose, this is important to get the proper dose and important in order to prevent air bubbles or air gaps in the liquid medication.
Znova POČASI potegnite beli nosilec bata ven, tako da je 0,1 ml preko predpisanega odmerka; to je pomembno, da boste dobili pravilen odmerek in da boste preprečili zračne mehurčke ali zračne presledke v tekočem zdravilu.
Against A/Indonesia 21 days after boosting with A/Indonesia
Proti A/Indonesia 21 dni po obnovitvi
Against A/Vietnam 21 days after boosting with A/Vietnam
Proti A/Vietnam 21 dni po obnovitvi
against calicivirus infection to reduce clinical signs,
proti okužbam s kalici virusi, za ublažitev kliničnih znamenj,
against calicivirus infection to reduce clinical signs,
proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj,,
against calicivirus infection to reduce clinical signs, against Chlamydophila felis infection to reduce clinical signs,
proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj, proti okužbam s Chlamydophila felis, za ublažitev kliničnih znamenj,
against calicivirus infection to reduce clinical signs, against Chlamydophila felis infection to reduce clinical signs, against feline panleucopenia to prevent mortality and clinical signs.
proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj, proti okužbam s Chlamydophila felis , za ublažitev kliničnih znamenj, proti mačji panleukopeniji, za preprečevanje smrtnosti in ublažitev kliničnih znamenj.
against calicivirus infection to reduce clinical signs, against Chlamydophila felis infection to reduce clinical signs, against feline panleucopenia to prevent mortality and clinical signs.
proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj, proti okužbam s Chlamydophila felis, za ublažitev kliničnih znamenj, proti mačji panleukopeniji, za preprečevanje smrtnosti in ublažitev kliničnih znamenj.
against calicivirus infection to reduce clinical signs, against feline panleucopenia to prevent mortality and clinical signs.
proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj, proti mačji panleukopeniji, za preprečevanje smrtnosti in ublažitev kliničnih znamenj.
Against each of the vaccine antigens, seroresponse rates and hSBA GMTs were high and similar after the two-dose series in infants 6-8 months of age and children, 13-15 and 24-26 months of age.
Po zaporednem cepljenju z dvema odmerkoma so bile stopnje serološkega odziva in vrednosti GST pri hSBA proti vsem antigenom cepiva visoke in podobne pri dojenčkih, starih od 6 do 8 mesecev in otrocih, starih 13-15 in 24-26 mesecev.
against feline panleucopenia to prevent mortality and clinical signs, against leukaemia to prevent persistent viraemia and clinical signs of the related disease.
proti mačji panleukopeniji, za preprečevanje smrtnosti in ublažitev kliničnih znamenj, proti leukemiji mačk, za preprečitev perzistentne viremije in ublažitev kliničnih znamenj bolezni.
against feline viral rhinotracheitis to reduce clinical signs,
Proti kužnemu rinotraheitisu mačk, za ublažitev kliničnih znamenj
against feline viral rhinotracheitis to reduce clinical signs,
proti kužnemu rinotraheitisu mačk, za ublažitev kliničnih znamenj,
against feline viral rhinotracheitis to reduce clinical signs, against calicivirus infection to reduce clinical signs.
proti kužnemu rinotraheitisu mačk, za ublažitev kliničnih znamenj, proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj.
Agalsidase beta is a recombinant form of human -galactosidase A and is produced by recombinant DNA technology using a mammalian Chinese Hamster Ovary (CHO) cell culture.
Agalzidaza beta je rekombinantna oblika človeškega encima α-galaktozidaze A, ki ga izdelujejo s tehnologijo rekombinantne DNA v sesalskih celičnih kulturah ovarijskih celic kitajskega hrčka (CHO - Chinese Hamster Ovary).
Agalsidase clearance was not influenced by weight in this population.
V tej populaciji telesna masa ni imela vpliva na očistek agalzidaze.
AGATE-1 –treatment-naïve or pegIFN +RBV experienced patients with compensated cirrhosis
AGATE-1 – še nezdravljeni ali že zdravljeni s kombinacijo pegIFN + RBV, s kompenzirano cirozo
age
tarostjo,
Age (28-87 years), race and disease state (low bone mass or osteoporosis; prostate or breast cancer) do not appear to significantly affect the pharmacokinetics of denosumab.
Kaže, da starost (28 – 87 let), rasa in stanje bolezni (majhna kostna masa ali osteoporoza; rak na prostati ali dojki) ne vplivajo pomembno na farmakokinetiko denosumaba.
Age (35-90 days / 91- 150 days), gender and haemangioma location (head / body) subgroups did not identify differences in response to propranolol.
Pri podskupinah po starosti (od 35 do 90 dni/od 91 do 150 dni), spolu in lokaciji hemangioma (glava/telo) ni bilo odkritih razlik v odzivu na propranolol.
Age (weeks), median [range]
Starost (tedni), mediana [interval]
Age (y)
Starost (l)
Age (years)
Starost (leta) (Razpon, leta)
Age (years)
tarost (leta)
Age (years) (b)
Starost (leta) (b)
Age (years), median [range] 13 [2 – 18]
Starost (leta), mediana [interval] 13 [2 – 18]
Age (years), median [range] 13 [2 – 18]
Starost (leta), mediana [razpon] 13 [2 – 18]
Age (years), median [range] 13 [2 – 18]
Starost (leta), mediana[interval] 13 [2 – 18]
Age (years): median (range)
Starost (leta): mediana (razpon)
Age (yr)
tarost (let)
Age [yrs (SD)]
Starost [let (SD)]
Age alone did not influence the paliperidone exposure.
Sama starost ni vplivala na izpostavljenost paliperidonu.
Age and bodyweight Dosage Frequency Infusion time
Starost in telesna masa Odmerjanje Pogostnost Čas infundiranja
Age and gender (when corrected for body weight) did not affect apparent clearance.
Starost in spol (korigirana na telesno maso) na navidezni očistek nista vplivala.
Age associated decreased renal clearance with an increase in AUC levels should be considered in elderly patients (see following paragraph ‘renal impairment’ and section 5.2).
Pri starejših bolnikih je treba upoštevati zmanjšan ledvični očistek zaradi starosti in povečanje AUC (glejte naslednji odstavek ‘Bolniki z ledvično okvaro' in poglavje 5.2).
Age associated decreased renal clearance with an increase in AUC levels should be considered in elderly patients (see following paragraph ‘renal impairment’ and section 5.2).
Pri starejših bolnikih je treba upoštevati zmanjšan ledvični očistek zaradi starosti in povečanje AUC (glejte naslednji odstavek ‘Bolniki z ledvično okvaro’ in poglavje 5.2).
Age associated decreased renal clearance with an increase in AUC levels should be considered in older patients (see following paragraph ‘renal impairment’ and section 5.2).
Pri starejših bolnikih je treba upoštevati zmanjšan ledvični očistek zaradi starosti in povečanje AUC (glejte naslednji odstavek ‘Bolniki z ledvično okvaro’ in poglavje 5.2).
Age at inclusion in the study was between 0.5 to 35 months.
Pri vključitvi v študijo je bila starost med 0,5 in 35 meseci.
Age at inclusion in the study was between 6 and 12 years old.
Pri vključitvi v študijo je bila starost bolnikov med 6 in 12 leti.
Age at inclusion was from 13 to 66 years.
Starost ob vključitvi je bila od 13 do 66 let.
Age at start of treatment or diagnosis
Starost na začetku zdravljenja ali diagnoze
Age at which treatment is started
Starost ob uporabi
Age category (years), n (%)
tarostna kategorija (leta), n (%)
Age category 1
0,43-1,05
Age category 1
<35 let
Age category 1
Starostna kategorija 1
Age category 2
Starostna kategorija 2
Age did not affect the regorafenib pharmacokinetics over the studied age range (29 – 85 years).
Starost ni vplivala na farmakokinetiko regorafeniba v preučevani starostni skupini (29 - 85 let).
Age did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data.
Glede na analizo populacijske farmakokinetike na podlagi podatkov iz I. in II. faze starost ni imela kliničnega pomena za farmakokinetiko sitagliptina.
Age did not influence the pharmacokinetic properties of nateglinide.
Starost ni vplivala na farmakokinetične lastnosti nateglinida.
Age does not impact the vedolizumab clearance in ulcerative colitis and Crohn’s disease patients based on the population pharmacokinetic analyses.
Analize populacijske farmakokinetike kažejo, da pri bolnikih z ulceroznim kolitisom ali s Crohnovo boleznijo starost ne vpliva na očistek vedolizumaba.
Age greater than 75 years was a significant predictor of carboxy- and desmethyl- dabrafenib plasma concentrations with a 40% greater exposure in subjects ≥75 years of age, relative to subjects <75 years old.
Starost nad 75 let je bila pomemben napovednik koncentracije karboksi- in dezmetildabrafeniba v plazmi; pri bolnikih v starosti ≥ 75 let je bila izpostavljenost 40 % večja kot pri bolnikih, starih < 75 let.
Age group
tarostna skupina
Age group 1 (n=113): 12 to 17 years treated with daptomycin dosed at 5 mg/kg or standard-of- care (SOC);
tarostna skupina 1 (n = 113): bolniki v starosti od 12 do 17 let so prejemali daptomicin v odmerkih 5 mg/kg ali standardno oskrbo;
Age group 2 (n=113): 7 to 11 years treated with daptomycin dosed at 7 mg/kg or SOC;
tarostna skupina 2 (n = 113): bolniki v starosti od 7 do 11 let so prejemali daptomicin v odmerkih 7 mg/kg ali standardno oskrbo;
Age group 65 - <75years
Starostna skupina od 65 do 75 let
Age group ≥75 years
Starostna skupina od 75. leta naprej
Age group†
Starostna skupina
Age group‡
Starostna skupina
Age had no impact on the exposure to rivastigmine in Alzheimer’s disease patients treated with Exelon transdermal patches.
Pri bolnikih z Alzheimerjevo boleznijo, ki so jih zdravili s transdermalnimi obliži Exelon, starost ni vplivala na izpostavljenost rivastigminu.
Age had no impact on the exposure to rivastigmine in Alzheimer’s disease patients treated with Prometax transdermal patches.
Pri bolnikih z Alzheimerjevo boleznijo, ki so jih zdravili s transdermalnimi obliži Prometax, starost ni vplivala na izpostavljenost rivastigminu.
Age had no impact on the exposure to rivastigmine in Alzheimer’s disease patients treated with rivastigmine transdermal patches.
Pri bolnikih z Alzheimerjevo boleznijo, ki so jih zdravili s transdermalnimi obliži Rivastigmin 3M Health Care Ltd., starost ni vplivala na izpostavljenost rivastigminu.
Age had no impact on the exposure to rivastigmine in Alzheimer’s disease patients treated with rivastigmine transdermal patches.
Pri bolnikih z Alzheimerjevo boleznijo, ki so jih zdravili s transdermalnimi obliži z rivastigminom, starost ni vplivala na izpostavljenost rivastigminu.
Age has been found to be a covariate in the population pharmacokinetic analysis of Cushing’s disease patients.
Pri analizi populacijske farmakokinetike pri bolnikih s Cushingovo boleznijo so ugotovili, da ima starost vlogo sospremenljivke.
Age has no clinically meaningful effect on pharmacokinetics of nicotinic acid (prolonged-release formulation) based on a composite analysis of subjects ages 18-65 years.
Glede na sestavljeno analizo preiskovancev, starih od 18 do 65 let, starost na farmakokinetiko nikotinske kisline (pripravka s podaljšanim sproščanjem) ne vpliva klinično pomembno.
Age has no effect on the pharmacokinetics of nelarabine or ara-G.
Starost ne vpliva na farmakokinetiko nelarabina ali ara-G.
Age is not a significant covariate in the population pharmacokinetic analysis of patients with acromegaly.
Pri analizi populacijske farmakokinetike pri bolnikih z akromegalijo so ugotovili, da starost kot sospremenljivka ni pomembna.
age of 6) for at least 1 day, until the
od 6 let) najmanj 1 dan, dokler
Age of onset was not known for 1 patient.
Za 1 bolnika nastop ni znan.
Age of vaccination
Starost pri cepljenju
Age older than 60 years, concomitant neurotoxicmedications, and diabetes may increase the risk for peripheral neuropathy.
Starost nad 60 let, sočasna uporaba nevrotoksičnih zdravil in sladkorna bolezen lahko povečajo tveganje za periferno nevropatijo.
Age or body weight
Starost ali telesna masa
Age over 60 and/ or prior myelosuppressive chemotherapy and/or extensive prior chemotherapy and/or a peak circulating stem cell count of less than 20 stem cells/microliter, have been identified as predictors of poor mobilization.
Kot napovedniki slabe mobilizacije so se (bodisi posamezno bodisi skupaj) izkazali starost nad 60 let, predhodna mielosupresivna kemoterapija, obsežna predhodna kemoterapija in največje število matičnih celic v obtoku manj kot 20 matičnih celic/mikroliter.
age over 75 years
tarost več kot 75 let,
Age range as described in the protocol for the study. bReduction in culture-confirmed influenza illness relative to injectable influenza vaccine. cT/LAIV demonstrated 55.7% (39.9, 67.6) fewer cases than injectable influenza vaccine in 3,686 infants and toddlers 6-23 months of age and 54.4% (41.8, 64.5) fewer cases in 4,166 children 24-59 months of age. dT/LAIV demonstrated 64.4% (1.4, 88.8) fewer cases than injectable influenza vaccine in 476 infants and toddlers 6-23 months of age and 48.2% (12.7, 70.0) fewer cases in 1,609 children 24-71 months of age.
Razpon starosti, kot je opisan v protokolu študije. bZmanjšanje s kulturo potrjene gripe v primerjavi s cepivom proti gripi za injiciranje. cS T/LAIV je bilo pri 3.686 dojenčkih in malčkih v starosti od 6 do 23 mesecev 55,7 % (39,9, 67,6) manj primerov kot s cepivom proti gripi za injiciranje, pri 4.166 otrocih v starosti od 24 do 59 mesecev pa 54,4 % (41,8, 64,5) manj primerov. dS T/LAIV je bilo pri 476 dojenčkih in malčkih v starosti od 6 do 23 mesecev 64,4 % (1,4, 88,8) manj primerov kot s cepivom proti gripi za injiciranje, pri 1.609 otrocih v starosti od 24 do 71 mesecev pa 48,2 % (12,7, 70,0) manj primerov.
Age rangea
Razpon starostia
Age Rangea
Starostni razpona
Age Stratum
Starost
Age was not found to be a significant factor on ofatumumab pharmacokinetics in a cross-study population pharmacokinetic analysis of patients ranging in age from 21 to 87 years of age.
Farmakokinetična analiza populacije več študij (bolniki v starosti od 21 do 87 let) je pokazala, da starost ni pomemben dejavnik farmakokinetike ofatumumaba.
Age WHO PS
starost WHO PS
Age yrs, median (range)
Starost v letih, mediana (razpon)
Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year*
tarost ≥ 50 let in naravna amenoreja ≥ 1 leto*,
Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year*
tarost ≥ 50 let in naravna amenoreja ≥ 1 leto*;
Age ≥ 75 years
starost ≥ 75 let
age ≥ 75 years
tarost ≥ 75 let
Age ≥75 years (n=119)
Starost ≥ 75 let (n = 119)
Age  70 years
tarost nad 70 let,
Age  50 years and naturally amenorrhoeic for  1 year*.
Starost  50 let in naravno amenoroična  1 leto.
Age, gender and race: No formal studies have been performed to assess the effects of these demographic factors.
Starost, spol in rasa: Formalne študije, ki bi ocenile vpliv teh demografskih faktorjev, niso bile opravljene.
Age, gender, race or body mass index (≥30 kg/m2, <30 kg/m2) did not influence the response to amlodipine/valsartan.
Starost, spol, rasa ali indeks telesne mase (≥ 30 kg/m2, < 30 kg/m2) niso vplivali na odziv na amlodipin/valsartan.
Age, gender, race or body mass index (≥30 kg/m2, <30 kg/m2) did not influence the response to Copalia.
Starost, spol, rasa ali indeks telesne mase (≥30 kg/m2, <30 kg/m2) niso vplivali na odziv na zdravilo Copalia.
Age, gender, race or body mass index (≥30 kg/m2, <30 kg/m2) did not influence the response to Dafiro.
Starost, spol, rasa ali indeks telesne mase (≥30 kg/m2, <30 kg/m2) niso vplivali na odziv na zdravilo Dafiro.
Age, gender, race or body mass index (≥30 kg/m2, <30 kg/m2) did not influence the response to Exforge.
Starost, spol, rasa ali indeks telesne mase (≥30 kg/m2, <30 kg/m2) niso vplivali na odziv na zdravilo Exforge.
Age, mean in years
Starost, povprečna v letih
Age, median (range) years
Starost, mediana leta (razpon)
Age, median, yrs
tarost, mediana, leta
Age-Median (years)
tarost-srednja (leta)
Age-related macular degeneration with occult with no classic lesions
Starostna degeneracija makule z okultnimi, a brez klasičnih lezij
Age: Based on the population pharmacokinetic analysis of data for 232 patients aged ≥ 65 years and 343 patients aged < 65 years, age has no statistically significant effect on bexarotene pharmacokinetics.
Starost: na podlagi populacijske farmakokinetične analize podatkov za 232 bolnikov, starih ≥ 65 let, in 343 bolnikov, starih < 65 let, starost ne vpliva statistično značilno na farmakokinetiko beksarotena.
Age: Pharmacokinetic differences have been identified between younger and elderly females (65 years) (AUC increases by about 25% and half-life is about 25% longer in the elderly), although the magnitude of these changes is not sufficient to justify adjustments to the dose.
Starost: ugotavljali so farmakokinetične razlike med mlajšimi in starejšimi ženskami ( 65 let) (pri starejših se AUC poviša za približno 25 %, razpolovni čas pa je daljši za približno 25 %), vendar obseg teh sprememb ni tolikšen, da bi upravičil prilagajanje odmerka.
Agenerase 15 mg/ml oral solution Amprenavir
Agenerase 15 mg/ml peroralna raztopina amprenavir
Agenerase 15 mg/ml oral solution.
Agenerase 15 mg/ml peroralna raztopina
Agenerase 150 mg soft capsules Amprenavir
Agenerase 150 mg mehke kapsule amprenavir
Agenerase 150 mg soft capsules are supplied in plastic bottles containing 240 soft capsules.
Zdravilo Agenerase v obliki 150 mg mehkih kapsul je na voljo v plastenkah, ki vsebujejo 240 mehkih kapsul.
Agenerase 150 mg soft capsules.
Agenerase 150 mg mehke kapsule
Agenerase 50 mg soft capsules Amprenavir
Agenerase 50 mg mehke kapsule amprenavir
Agenerase 50 mg soft capsules are supplied in plastic bottles containing 480 soft capsules.
Zdravilo Agenerase v obliki 50 mg mehkih kapsul je na voljo v plastenkah, ki vsebujejo 480 mehkih kapsul.
Agenerase 50 mg soft capsules.
Agenerase 50 mg mehke kapsule
Agenerase capsules (without the boosting effect of ritonavir) have been studied in patients with liver impairment.
Uporaba kapsul Agenerase (brez ritonavirja, ki bi okrepil njihov učinek) je bila raziskana pri bolnikih z oslabljenim delovanjem jeter.
Agenerase capsules are contraindicated in patients with severe hepatic impairment when used in combination with ritonavir (see section4.3).
Uporaba kapsul Agenerase v kombinaciji z ritonavirjem je kontraindicirana pri bolnikih s hudo obliko oslabljenega delovanja jeter (glejte poglavje 4.3).
Agenerase capsules should be swallowed whole with water or another drink.
Kapsule Agenerase morate pogoltniti cele skupaj z vodo ali drugo pijačo.
Agenerase in combination with ritonavir is contraindicated in patients with severe hepatic impairment.
Zdravilo Agenerase je v kombinaciji z ritonavirjem kontraindicirano pri bolnikih s hudo obliko oslabljenjega delovanja jeter.
Agenerase is administered orally and can be taken with or without food.
Zdravilo Agenerase se uporablja peroralno in se sme jemati s hrano ali brez nje.
Agenerase must not be administered concurrently with medicinal products with narrow therapeutic windows containing active substances that are substrates of cytochrome P450 3A4 (CYP3A4).
Zdravilo Agenerase se ne sme dajati sočasno z zdravili z ozko terapevtsko širino, ki vsebujejo učinkovine, ki so substrati za citokrom P450 3A4 (CYP3A4).